GlassScriptPhysician profile
Rabih Tabet
NPI 1104277888
$1,962.32
in general payments reported to CMS, 2019-2025
13 companies · $639 in 2025
The $639 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,324 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,962.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spectrawave, INC | $294.14 | 2024 | Starlight Imaging Catheter, Hypervue Imaging System |
| Medtronic, INC. | $251.55 | 2024 | Onyx Frontier |
| Abiomed | $238.84 | 2024-2025 | Impella |
| Abbott Laboratories | $236.51 | 2024 | Ultreon, Nc Trek Neo, Diamondback Coronary |
| Asahi Intecc USA, INC. | $235.15 | 2024-2025 | Asahi Coronary Wires, Peripheral Vascular |
| Philips North America LLC | $168.40 | 2024 | (Bq9) Coronary Ivus, (9266) Elca, (6571) Eagle Eye |
| Veryan Medical Incorporated | $141.78 | 2025 | Biomimics 3d Vascular Stent System |
| Novo Nordisk INC | $114.34 | 2024 | |
| Cook Medical LLC | $104.06 | 2025 | Zilver Ptx |
| Bard Peripheral Vascular, INC. | $61.00 | 2025 | Rotarexs 6 F X 135 Cm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.30 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $43.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $18.96 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabih Tabet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.